ADRB2 and heart failure: Finally, given that modification of β-AR signaling has clearly been established as a molecular contributor to the evolution of heart failure, changes in the G protein and the receptor ratio could participate in the atypical pharmacology of β-AR agonists and the onset and/or worsening of the disease.